Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M. Gounder, Albiruni Ryan Abdul Razak, Mark A. Dickson et al.|Journal of Clinical Oncology|2016Cited by 165
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)John Kuruvilla, Mansoor Raza Mirza, Martin Gutierrez et al.|Blood|2013Cited by 30